Abstract
DNA methylation (DNAm) silences gene expression and may play a role in immune dysregulation that is characteristic of adolescent/young adult Hodgkin lymphoma (AYAHL). We used the Infinium HumanMethylation27 BeadChip to quantify DNAm in blood (N = 9 pairs, mean age 57.4 y) or saliva (N = 36 pairs, mean age 50.0 y) from long-term AYAHL survivors and their unaffected co-twins. Epigenetic aging (DNAm age) was calculated using previously described methods and compared between survivors and co-twins using paired t-tests and analyses were stratified by sample type, histology, sex, age at sample collection and time since diagnosis. Differences in blood DNAm age were observed between survivors and unaffected co-twins (64.1 vs. 61.3 years, respectively, p = .04), especially in females (p = .01); no differences in saliva DNAm age were observed. Survivors and co-twins had 74 (in blood DNA) and 6 (in saliva DNA) differentially methylated loci. Our results suggest persistent epigenetic aging in AYAHL survivors long after HL cure.
Acknowledgements
This work was supported by the National Institutes of Environmental Health Science (1R01ESO15150-01 to TMM) and from the National Cancer Institute (1R03CA110836 to WC), the Leukemia Lymphoma Society (TRP-6137-07 to WC), the Department of Defense Peer-Reviewed Medical Research Program (PR054600 to WC), and the American Society of Hematology Bridge Grant Program (to WC). We would like to thank the participants and staff of the International Twin Registry at University of Southern California for their valuable contributions. The authors assume full responsibility for analyses and interpretation of these data.
Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10.1080/10428194.2018.1533128.
Data availability
The data that support the findings of this study are available from the corresponding author, W.C., upon reasonable request.